German health care and science group Merck has sealed a deal to bolster its cancer treatment portfolio with a $3.9-billion ...

German healthcare and materials group Merck KGaA has struck a deal, it said on Monday, to acquire U.S. biotech company ...

Germany's Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business.

Germany's Merck is on the verge of a billion-euro takeover of US biopharmaceutical company Springworks Therapeutics, with the ...

Merck KGaA agreed to buy SpringWorks Therapeutics Inc., a maker of medicines for cancer and rare diseases, to boost its ...

The acquisition provides Merck with immediate access to SpringWorks' approved rare cancer therapies - Ogsiveo for aggressive soft tissue tumors and the recently approved Gomekli for nerve sheath ...

Domino’s Pizza reports earnings, Nvidia faces stiff competition in China, and Spirit AeroSystems finalizes a deal to transfer ...

Shares of SpringWorks Therapeutics climbed after The Wall Street Journal reported that Germany's Merck KGaA is nearing a $3.5 billion deal for the U.S. biopharmaceutical company. SpringWorks stock ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

The global 3D bioprinting market is set to witness a growth rate of 12-15% in the next 5 years. Rising demand for organ ...